
Acutaas Chemical Q2 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
Yes
Capex
Yes
4 of 5 growth signals are positive — a strong management growth story.
Full analysisRevenue guidance
Category 2- AMI Organics targets a 30% revenue growth for FY25, revised upward from 25%, driven by strong order book and forecast.
- The company expects a consistent ~25% CAGR growth in the medium term based on a robust product pipeline and existing CDMO contracts.
- CDMO business to scale up materially from Q3 FY25 onwards, providing sizable additional revenue.
- Ankleshwar unit at full utilization is expected to generate around ₹900 crore revenue, with 310 crore CAPEX invested.
- The ramp-up for the Fermion contract and CDMO projects will continue through FY25, with full capacity utilization expected by FY26.
- Specialty Chemicals (excluding Baba Fine Chem) is growing over 25%, and pharma intermediates grew 53% Y-o-Y in Q2 FY25.
- New geographic expansions (e.g., Korea, Japan) and product launches support growth beyond FY25.
- EBITDA margins expected to improve on operational leverage and stabilized pricing through FY25-FY26.
See what Acutaas Chemical management said on margin guidance — free account, 30 seconds.
Fundraise plans
Yes- No explicit mention of any new fundraising through debt or equity at present or in the near future.
- The company has recently completed a QIP (Qualified Institutional Placement) raising around Rs. 500 crore, used mainly for debt repayment (~Rs. 250 crore) and CAPEX.
- Current cash and cash equivalents stand at Rs. 279 crore.
- No mention of plans for further QIP or debt raising during FY25 or FY26.
- CAPEX guidance for FY25 is Rs. 250 crore and FY26 is Rs. 40 crore, expected to be funded through internal accruals and existing resources.
- Management highlighted cautious investment approach, especially regarding the EV-related JV, waiting for clear visibility before committing funds.
See what Acutaas Chemical management said on order book — free account, 30 seconds.
Capex plans
Yes- FY25 CAPEX for AMI Organics is around ₹250 crore, including:
- - ₹70 crore for Unit 2 Ankleshwar site (expected completion Q3 FY25)
- - ₹100 crore for electrolyte additive project (capacity 2000 MT for VC and FEC, completion expected by Q1 FY26)
- - ₹60 crore for captive solar power plant (completion expected by end Q3 FY25)
- - ₹30 crore for regular maintenance CAPEX
- FY26 CAPEX is expected to be around ₹40 crore primarily for maintenance.
- Strategic investments include:
- - Expansion of Ankleshwar unit capacity to 442 KL in three blocks, fully operational over three years.
- - Electrolyte additive capacity build-up following long-term contracts.
- - Careful evaluation and cautious investment in EV-related projects due to deferrals in the EV market.
- - Potential joint venture with Enchem under discussion, status quo currently.
- ₹88 crore from QIP reserved for general corporate purposes and future opportunities.
Track Acutaas Chemical — get its next earnings analysis in your feed
How does Acutaas Chemical rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Acutaas Chemical rank in Pharmaceuticals & Biotechnology?
Compare Acutaas Chemical against every Pharmaceuticals & Biotechnology company (Q2 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Acutaas Chemical's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lasa Supergeneri (Q2 FY27)
306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra
- Themis Medicare (Q2 FY27)
Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q
- Panacea Biotec (Q2 FY27)
September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Biofil Chemicals (Q2 FY27)
Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem